Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.
Wolfgang M BrücklMartin ReckAchim RittmeyerJens KollmeierClaas WesselerGunther H WiestPetros ChristopoulosAmanda TufmanPetra HoffknechtBernhard UlmFabian ReichJoachim H FickerEckart LaackPublished in: Clinical Medicine Insights. Oncology (2020)
R + D is a highly effective and safe third-line treatment after failure of second-line programmed cell death protein 1/programmed cell death-ligand 1 (PD1/PD-L1)-derived ICI therapy irrespective of NSCLC histology. As there may be synergistic effects of second- and third-line treatments, this sequence is a very suitable option for patients not treated with first-line ICI. In addition, R + D should continue to be investigated as a second-line treatment option after failure of chemotherapy plus ICI in the palliative first-line treatment.